Sign in
Taking peopleNo phase

Blood clots and bleeding during blood thinner treatment in people with cancer

Looks at clots and bleeding in adults with cancer taking blood thinners.

Key facts

Who runs it
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Where
Italy2 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
Thromboembolic and Hemorrhagic Complications of Anticoagulant Treatment in Patients With CAT
Status
Recruiting
People taking part
1,000 people, planned
Started
2 Jan 2016
Expected to end
31 Dec 2027
Type of study
Observational
Record updated
4 December 2024

Who can take part

The trial is looking for adults with cancer who have a blood clot in a vein or in the lungs. It follows how they do on blood-thinning treatment.

Age
18 years and older
Sex
All sexes
Disease stage
A blood clot in a vein at any site, including a clot linked to a central venous catheter (CVC), or a clot in the lungs (pulmonary embolism), with or without symptoms. People must also have a solid or blood cancer that is active or being treated.
Earlier treatment
People are treated with low molecular weight heparin or direct oral anticoagulants (DOACs), as decided by their doctor.
Show the full registry criteria (7)Hide the full registry criteria

Who can take part

  • Age ≥ 18 years
  • Diagnosis of venous thrombosis at any site
  • Diagnosis of CVC-related venous thrombosis
  • Diagnosis of pulmonary embolism, both symptomatic and incidental
  • Diagnosis of solid or hematological neoplasm, either under treatment or active
  • Obtaining of Informed Consent

Who cannot take part

  • None

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Venous thromboembolism

This trial is currently available in Italy.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The study is classified as an observational pharmacological study, spontaneous, monocentric, and both retrospective and prospective for adult patients with a diagnosis of venous thromboembolism in the context of neoplasia, followed at the SSD Angiology and Coagulation Disorders of the IRCCS Azienda Ospedaliero-Universitaria di Bologna and The Cardiovascular Medicine Department, specifically the Angiology Unit, of the IRCCS Arcispedale S. Maria Nuova in Reggio Emilia, from 01/01/2016 to 30/06/2027. The study, including data analysis, is expected to conclude by 31/12/2027.

Read full original descriptionShow less

Patients were treated according to clinical practice, in accordance with the physician's judgment and the information provided in the product's technical datasheet for any concomitant therapies administered as per clinical practice.

The primary objective of the study is to evaluate the frequency of thrombotic and hemorrhagic complications during treatment with low molecular weight heparin or direct oral anticoagulants in patients with venous thromboembolism and solid and hematological neoplasms attending outpatient care at the SSD Angiology and Coagulation Disorders of the IRCCS AOUBO and The Cardiovascular Medicine Department, specifically the Angiology Unit, of the IRCCS Arcispedale S. Maria Nuova in Reggio Emilia, following the initiation of anticoagulant therapy (LMWH or DOACs).

The secondary objectives of the study are:

* To identify risk factors for hemorrhagic complications and bleeding risk during anticoagulant treatment for CAT; * To assess the applicability and reliability of a score, which is not currently in use in clinical practice, without impacting the care process and clinical decisions, in a prospective cohort of patients with CAT.

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Thromboembolic and Hemorrhagic Complications of Anticoagulant Treatment in Patients With CAT (Cancer Associated Thrombosis)
Plain-language title
Blood clots and bleeding during blood thinner treatment in people with cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT06714734, who can take part
Record updated
4 December 2024